Cargando…
Tumor Targeting of (211)At-Labeled Antibody under Sodium Ascorbate Protection against Radiolysis
[Image: see text] Astatine-211 ((211)At) is an alpha emitter applicable to radioimmunotherapy (RIT), a cancer treatment that utilizes radioactive antibodies to target tumors. In the preparation of (211)At-labeled monoclonal antibodies ((211)At-mAbs), the possibility of radionuclide-induced antibody...
Autores principales: | Takashima, Hiroki, Ohnuki, Kazunobu, Manabe, Shino, Koga, Yoshikatsu, Tsumura, Ryo, Anzai, Takahiro, Wang, Yang, Yin, Xiaojie, Sato, Nozomi, Shigekawa, Yudai, Nambu, Akihiro, Usuda, Sachiko, Haba, Hiromitsu, Fujii, Hirofumi, Yasunaga, Masahiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906747/ https://www.ncbi.nlm.nih.gov/pubmed/36573995 http://dx.doi.org/10.1021/acs.molpharmaceut.2c00869 |
Ejemplares similares
-
Stabilization of an (211)At-Labeled Antibody
with Sodium Ascorbate
por: Manabe, Shino, et al.
Publicado: (2021) -
Radioimmunotherapy with an (211)At‐labeled anti–tissue factor antibody protected by sodium ascorbate
por: Takashima, Hiroki, et al.
Publicado: (2021) -
Protection from contamination by (211)At, an enigmatic but promising alpha-particle-emitting radionuclide
por: Ohnuki, Kazunobu, et al.
Publicado: (2022) -
Evaluation of the antitumor mechanism of antibody‐drug conjugates against tissue factor in stroma‐rich allograft models
por: Tsumura, Ryo, et al.
Publicado: (2019) -
ET-05 PRECLINICAL STUDY OF AN ANTI-HUMAN TISSUE FACTOR ANTIBODY-DRUG CONJUGATE IN A MALIGNANT GLIOMA XENOGRAFT MODEL
por: Takashima, Hiroki, et al.
Publicado: (2019)